Download PDF
Der Nuklearmediziner 2014; 37(04): 242-249
DOI: 10.1055/s-0034-1394377
Pädiatrische Nuklearmedizin
© Georg Thieme Verlag KG Stuttgart · New York

Positronenemissionstomografische Diagnostik kindlicher Sarkome

Positron Emission Tomography in the Diagnosis of Sarcomas in Childhood and Adolescence
A. Vrachimis
1   Klinik für Nuklearmedizin, Universitätsklinikum Münster
,
M. Schäfers
1   Klinik für Nuklearmedizin, Universitätsklinikum Münster
,
U. Dirksen
2   Klinik und Poliklinik für Kinder und Jugendmedizin – Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Münster
,
M. Weckesser
1   Klinik für Nuklearmedizin, Universitätsklinikum Münster
› Author Affiliations
Further Information

Publication History

Publication Date:
24 November 2014 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Bei den Sarkomen des Kindesalters handelt es sich um eine heterogene Gruppe von Tumoren, für die wenige allgemeingültige Aussagen getroffen werden können. Für Ewing-Sarkome und Rhabdomyosarkome ist die FDG-PET ein exzellentes Instrument zur Primärtumor-Suche und für den Nachweis von Weichteil- oder Knochenmetastasen. In Verbindung mit der CT, die Lungenmetastasen mit höchster Sensitivität zeigt, kann die PET/CT für das Staging gut eingesetzt werden. Für die Operationsplanung wird in der Regel jedoch der MRT der Vorzug zu geben.

Die Metastasen von Osteosarkomen verhalten sich demgegenüber anders, und sind in der Regel in Skelett-Szintigrafie, CT und MRT besser zu diag­nostizieren.

Die PET/CT sollte wo immer möglich im Rahmen klinischer Studien systematisch evaluiert werden.

Abstract

Paediatric sarcomas are a heterogeneous group of tumors, for which few generally accepted statements can be made. In Ewing sarcomas and Rhabdomyosarcomas FDG-PET is an excellent instrument to assess metabolic activity of the primary tumors and to identifying nodal and soft tissue metastases or metastastic bone involvement. In combination with CT, which shows pulmonary metastases with the highest sensitivity, PET/CT can be applied optimally for staging. However, MRI still remains superior for planning surgery. In contrast, metastases of osteosarcomas behave differently and bone scintigraphy, CT and MRI are in most cases sufficient for stag­ing. PET/CT should be systematically evaluated in clinical studies whenever possible.

Schlüsselwörter

PET - Sarkom - Kinder - Jugendliche - FDG

Key words

PET - sarcoma - childhood - adolescence - FDG
 

  • Literatur

  • 1 Baum SH, Fruhwald M, Rahbar K et al. Contribution of PET/CT to prediction of outcome in children and young adults with rhabdomyosarcoma. J Nucl Med 2011; 52: 1535-1540
    CrossrefPubMedGoogle Scholar
  • 2 Byun BH, Kong CB, Lim I et al. Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential F-FDG PET/CT and MRI. Eur J Nucl Med Mol Imaging 2014;
    PubMedGoogle Scholar
  • 3 Denecke T, Hundsdorfer P, Misch D et al. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters. Eur J Nucl Med Mol Imaging 2010; 37: 1842-1853
    CrossrefPubMedGoogle Scholar
  • 4 Dharmarajan KV, Wexler LH, Gavane S et al. Positron emission tomography (PET evaluation after initial chemotherapy and radiation therapy predicts local control in rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2012; 84: 996-1002
    CrossrefPubMedGoogle Scholar
  • 5 Eugene T, Corradini N, Carlier T et al. (18)F-FDG-PET/CT in initial staging and assessment of early response to chemotherapy of pediatric rhabdomyosarcomas. Nucl Med Commun 2012; 33: 1089-1095
    CrossrefPubMedGoogle Scholar
  • 6 Federico SM, Spunt SL, Krasin MJ et al. Comparison of PET-CT and conventional imaging in staging pediatric rhabdomyosarcoma. Pediatr Blood Cancer 2013; 60: 1128-1134
    CrossrefPubMedGoogle Scholar
  • 7 Franzius C, Bielack S, Flege S et al. Prognostic significance of (18)F-FDG and (99 m)Tc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med 2002; 43: 1012-1017
    PubMedGoogle Scholar
  • 8 Gerth HU, Juergens KU, Dirksen U et al. Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors. J Nucl Med 2007; 48: 1932-1939
    CrossrefPubMedGoogle Scholar
  • 9 Gupta K, Pawaskar A, Basu S et al. Potential role of FDG PET ­imaging in predicting metastatic potential and assessment of therapeutic ­response to neoadjuvant chemotherapy in Ewing sarcoma family of tumors. Clin Nucl Med 2011; 36: 973-977
    CrossrefPubMedGoogle Scholar
  • 10 Hawkins DS, Conrad EU, Butrynski JE et al. [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer 2009; 115: 3519-3525
    CrossrefPubMedGoogle Scholar
  • 11 Juergens KU, Weckesser M, Stegger L et al. Tumor staging using whole-body high-resolution 16-channel PET-CT: does additional low-dose chest CT in inspiration improve the detection of solitary pulmonary nodules?. Eur Radiol. 2006. 16. 1131-1137
    Google Scholar
  • 12 Jürgens H, Paulussen M, Zoubek A. Ewing-Tumoren. In: Gadner H, Gaedicke G, Niemeyer Ch, Ritter J. (eds.) Pädiatrische Hämatologie und Onkologie. Springer-Verlag; 2006
    CrossrefGoogle Scholar
  • 13 Kaatsch PSC. German Childhood Cancer Registry – Report 2012 (1980–2012). Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI at the University Medical Center of the Johannes Gutenberg University Mainz 2013;
    PubMedGoogle Scholar
  • 14 Klem ML, Grewal RK, Wexler LH et al. PET for staging in rhabdomyosarcoma: an evaluation of PET as an adjunct to current staging tools. J Pediatr Hematol Oncol 2007; 29: 9-14
    CrossrefPubMedGoogle Scholar
  • 15 Lisle JW, Eary JF, O’Sullivan J et al. Risk assessment based on FDG-PET imaging in patients with synovial sarcoma. Clin Orthop Relat Res 2009; 467: 1605-1611
    CrossrefPubMedGoogle Scholar
  • 16 Newman EN, Jones RL, Hawkins DS. An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma. Pediatr Blood Cancer 2013; 60: 1113-1117
    CrossrefPubMedGoogle Scholar
  • 17 Quartuccio N, Treglia G, Salsano M et al. The role of Fluorine-18-Fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma. Radiol Oncol 2013; 47: 97-102
    PubMedGoogle Scholar
  • 18 Ricard F, Cimarelli S, Deshayes E et al. Additional Benefit of F-18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcoma. Clin Nucl Med 2011; 36: 672-677
    CrossrefPubMedGoogle Scholar
  • 19 Sharma P, Khangembam BC, Suman KC et al. Diagnostic accuracy of 18 F-FDG PET/CT for detecting recurrence in patients with primary skeletal Ewing sarcoma. Eur J Nucl Med Mol Imaging 2013; 40: 1036-1043
    CrossrefPubMedGoogle Scholar
  • 20 Tateishi U, Hosono A, Makimoto A et al. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma. Ann Nucl Med 2009; 23: 155-161
    CrossrefPubMedGoogle Scholar
  • 21 Treuner J, Brecht IB. Weichteilsarkome. In: Gadner H, Gaedicke G, Niemeyer Ch, Ritter J. eds. Springer-Verlag; 2006
    CrossrefGoogle Scholar
  • 22 Tsai LL, Drubach L, Fahey F et al. [18 F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation. J Neurooncol 2012; 108: 469-475
    CrossrefPubMedGoogle Scholar
  • 23 Ulaner GA, Magnan H, Healey JH et al. Is methylene diphosphonate bone scan necessary for initial staging of Ewing sarcoma if 18 F-FDG PET/CT is performed?. AJR Am J Roentgenol 2014; 202: 859-867
    CrossrefPubMedGoogle Scholar
  • 24 Volker T, Denecke T, Steffen I et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007; 25: 5435-5441
    CrossrefPubMedGoogle Scholar
  • 25 Vrachimis A, Dirksen U, Wessling J et al. PET surveillance of patients with Ewing sarcomas of the trunk: Must the lower legs be included?. Nuklearmedizin 2010; 49: 183-186
    Article in Thieme ConnectPubMedGoogle Scholar